Abstract
Objective: Biotransformation of metoprolol to α-hydroxymetoprolol (HM) and O-demethylmetoprolol (ODM) is mediated by CYP2D6. The selective serotonin reuptake inhibitors (SSRIs) are known to inhibit CYP2D6. The aim was to study in vitro the potential inhibitory effect of SSRIs on metoprolol biotransformation.
Methods: Using microsomes from two human livers, biotransformation of metoprolol to α-hydroxymetoprolol (HM) and O-demethylmetoprolol (ODM) as a function of the concentrations of the SSRIs and of some of their metabolites was studied.
Results: The kinetics of the formation of both metabolites are best described by a biphasic enzyme model. The estimated values of Vmax and kM for the high affinity site are for the α-hydroxylation in human liver HL-1 32 pmol mg−1 min−1 and 75 μmol · l−1 respectively, and in human liver HL-9 39 pmol mg−1 · min−1 and 70 μmol · l−1 respectively; for the O-demethylation in HL-1 131 pmol mg−1 min−1 and 95 μmol · l−1 respectively, and in HL-9 145 pmol mg−1 min−1 and 94 μmol · l−1 respectively. Quinidine is for both pathways a potent inhibitor of the high-affinity site, with Ki values ranging from 0.03 to 0.18 μmol · l−1. Fluoxetine, norfluoxetine and paroxetine are likewise potent inhibitors, with Ki values ranging from 0.30 to 2.1 μmol · l−1 fluvoxamine, sertraline, desmethylsertraline, citalopram and desmethylcitalopram are less potent inhibitors, with Ki values above 10 μmol · l−1.
Conclusion: The rank order of the SSRIs for inhibition of metoprolol metabolism is comparable to that reported in the literature for other CYP2D6 substrates, with fluoxetine, norfluoxetine and paroxetine being the most potent. These findings need further investigation to determine their clinical relevance.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 24 October 1997 / Accepted: 17 January 1998
Rights and permissions
About this article
Cite this article
Belpaire, F., Wijnant, P., Temmermann, A. et al. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. E J Clin Pharmacol 54, 261–264 (1998). https://doi.org/10.1007/s002280050456
Issue Date:
DOI: https://doi.org/10.1007/s002280050456